Last Updated on October 17, 2024 by The Health Master
Collaboration Between Belarus and Indian Pharma Companies
Belarus, a crucial gateway to the Central European market, is seeking collaboration with Indian pharmaceutical companies to establish joint ventures in the fields of anti-cancer and immunosuppressant drugs.
This development holds significant potential for the Indian pharma industry.
Exploring Business Opportunities
Lakshmi Prasanna, Director of Regulatory Affairs at Pharmexcil, revealed that discussions are underway to explore business opportunities in additional areas such as biosimilars, complex generics, and other advanced therapies.
Growing Import Relationship
India ranks fifth among Belarus’s top 10 formulation import partners, with imports valued at US$ 44.98 million in 2019, US$ 46.94 million in 2020, and US$ 51.50 million in 2021.
Locally produced products currently hold an 80% market share in Belarus.
Market Overview
As of 2022, Belarus had a market size of US$ 1.42 billion.
The patented medicine market share accounted for 10.11% (valued at US$ 143.5 million), generics held a share of 53.2% (worth US$ 754.6 million), and the over-the-counter (OTC) market share stood at 36.7%.
Strategic Location
Situated in the center of Europe, Belarus plays a crucial role in connecting the Commonwealth of Independent States (CIS) countries with Western European states.
It shares borders with Poland, Lithuania, Latvia, Russia, and Ukraine, making it strategically important for trade development.
State-Owned Dominance
The Belarus Pharmaceutical Holdings Companies, led by “Belpharmprom,” dominate the pharmaceutical industry in Belarus, primarily comprising state-owned enterprises.
Indian Presence in Belarus
Indian pharmaceutical companies have established a significant presence in Belarus.
BDR Pharmaceuticals International Pvt Ltd, for instance, invested US$ 13 million to acquire a controlling stake in a Belarusian government-owned pharma unit.
Joint Ventures
Belarusian Belmedpreparaty and Novalok-India have formed a joint venture called Lok-Beta Pharma India Pvt Ltd.
Cipla’s Investment
Cipla, a prominent Indian pharma company, launched the Yusuf Hamied Pharma R&D Center in August 2018, located at the premises of the Academfarm of the National Academy of Science (NAS) in Minsk, Belarus. Cipla invested one million USD into this initiative.
Natco Pharma’s Contribution
Natco Pharma took part in the establishment of NatiVita, a state-of-the-art biotechnological and generic medicines production facility.
The project received investments of US$ 15 million from Natco Pharma (India), Biocad (Russia), Belarusian medicine distributor VitVar, and Lithuanian investment company ZIA Valda.
Successful Belarusian-Indian Pharmaceutical Forum
The Belarus-Indian Pharmaceutical Forum, organized by Pharmexcil in collaboration with the Belarus Pharmaceutical Holdings Company “Belpharmprom,” concluded successfully between May 23 and May 26, 2023, in Minsk, Belarus.
The forum took place during the XXVIII International Medical Forum “Healthcare of Belarus.”
Pharma Companies to mention excipients on medicine strips, soon
Medical Stores to come under Hospital Protection Act: Minister assures
Machines stolen from sealed pharma factory in Baddi
Airlocks in the Pharma Industry: An essential component
Govt prohibits 14 FDC Drugs, Citing Safety Concerns
CDSCO gives approval for Tremelimumab combination in India
Gang selling fake medicines busted in Delhi, UP
USFDA warns about safety risks of tailored weight-loss drugs
Line clearance and maintenance in manufacturing: A comprehensive guide
Difference between Validation and Calibration in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
